Value of benralizumab in the treatment of severe eosinophilic asthma

Bronchial asthma is a common chronic airway disease. The symptoms of some patients treated according to the guidelines are still not satisfactorily controlled, especially in eosinophilic asthma patients who are symptomatic despite treatment with inhaled corticosteroids and a long-acting beta2-agonist. Benralizumab is a humanized interleukin-5 receptor antibody. In this paper, we will review the fundamental characteristics of benralizumab as well as its clinical evaluation, safety, and application prospect in the treatment of eosinophilic asthma. Key words: Benralizumab; Asthma; Eosinophils; Interleukin-5